KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $155.1 million.

  • Recursion Pharmaceuticals' Total Current Liabilities rose 4244.27% to $155.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 4244.27%. This contributed to the annual value of $187.5 million for FY2024, which is 10121.28% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Total Current Liabilities is $155.1 million, which was up 4244.27% from $164.0 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Total Current Liabilities registered a high of $187.5 million during Q4 2024, and its lowest value of $26.9 million during Q1 2021.
  • For the 5-year period, Recursion Pharmaceuticals' Total Current Liabilities averaged around $95.9 million, with its median value being $93.2 million (2023).
  • In the last 5 years, Recursion Pharmaceuticals' Total Current Liabilities surged by 22719.36% in 2022 and then tumbled by 2446.14% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Current Liabilities (Quarter) stood at $46.7 million in 2021, then skyrocketed by 114.89% to $100.3 million in 2022, then dropped by 7.08% to $93.2 million in 2023, then surged by 101.21% to $187.5 million in 2024, then dropped by 17.27% to $155.1 million in 2025.
  • Its Total Current Liabilities stands at $155.1 million for Q3 2025, versus $164.0 million for Q2 2025 and $142.0 million for Q1 2025.